97 related articles for article (PubMed ID: 1994549)
1. Characterization of the in vitro sensitivity of human lymphoid and hematopoietic progenitors to L-leucyl-L-leucine methyl ester.
Pecora AL; Bordignon C; Fumagalli L; Radziejewski C; Small TN; Pekle K; O'Reilly RJ; Keever CA
Transplantation; 1991 Feb; 51(2):524-31. PubMed ID: 1994549
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo purging of allogeneic marrow with L-Leucyl-L-leucine methyl ester. A phase I study.
Rosenfeld CS; Thiele DL; Shadduck RK; Zeigler ZR; Schindler J
Transplantation; 1995 Oct; 60(7):678-83. PubMed ID: 7570976
[TBL] [Abstract][Full Text] [Related]
3. The immunosuppressive activity of L-leucyl-L-leucine methyl ester: selective ablation of cytotoxic lymphocytes and monocytes.
Thiele DL; Lipsky PE
J Immunol; 1986 Feb; 136(3):1038-48. PubMed ID: 2934477
[TBL] [Abstract][Full Text] [Related]
4. Leu-Leu-OMe sensitivity of human activated killer cells: delineation of a distinct class of cytotoxic T lymphocytes capable of lysing tumor targets.
Thiele DL; Lipsky PE
J Immunol; 1986 Aug; 137(4):1399-406. PubMed ID: 3488348
[TBL] [Abstract][Full Text] [Related]
5. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
6. Lethal graft-vs-host disease across major histocompatibility barriers: requirement for leucyl-leucine methyl ester sensitive cytotoxic T cells.
Thiele DL; Charley MR; Calomeni JA; Lipsky PE
J Immunol; 1987 Jan; 138(1):51-7. PubMed ID: 2946780
[TBL] [Abstract][Full Text] [Related]
7. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.
Grimm EA; Ramsey KM; Mazumder A; Wilson DJ; Djeu JY; Rosenberg SA
J Exp Med; 1983 Mar; 157(3):884-97. PubMed ID: 6601174
[TBL] [Abstract][Full Text] [Related]
8. Effects of L-leucyl-L-leucine methyl ester on human marrow and protection of progenitor cells by IL-1.
Rosenfeld CS
Int J Cell Cloning; 1992 Jul; 10(4):249-53. PubMed ID: 1645032
[TBL] [Abstract][Full Text] [Related]
9. Leucyl-leucine methyl ester-treated haploidentical donor lymphocyte infusions can mediate graft-versus-leukemia activity with minimal graft-versus-host disease risk.
Hsieh MH; Varadi G; Flomenberg N; Korngold R
Biol Blood Marrow Transplant; 2002; 8(6):303-15. PubMed ID: 12108916
[TBL] [Abstract][Full Text] [Related]
10. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
[TBL] [Abstract][Full Text] [Related]
11. Differential sensitivity of cytotoxic T lymphocytes and lymphokine-activated killer cells to inhibition by L-ornithine.
Susskind BM; Sekar J; Tandon PM; Lind DS; Bear HD
Cell Immunol; 1991 Mar; 133(1):41-54. PubMed ID: 1899361
[TBL] [Abstract][Full Text] [Related]
12. Depletion of NK cells with the lysosomotropic agent L-leucine methyl ester and the in vitro generation of NK activity from NK precursor cells.
Shau H; Golub SH
J Immunol; 1985 Feb; 134(2):1136-41. PubMed ID: 3871208
[TBL] [Abstract][Full Text] [Related]
13. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
[TBL] [Abstract][Full Text] [Related]
14. Lethal graft-vs-host disease induced by a class II MHC antigen only disparity is not mediated by cytotoxic T cells.
Thiele DL; Bryde SE; Lipsky PE
J Immunol; 1988 Nov; 141(10):3377-82. PubMed ID: 3053897
[TBL] [Abstract][Full Text] [Related]
15. Generalized toxicity of L-leucyl-leucine-methyl ester for lymphocyte functions.
Mowat AM; Leck PA
Immunology; 1990 Apr; 69(4):564-9. PubMed ID: 2335375
[TBL] [Abstract][Full Text] [Related]
16. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells.
Kasid A; Bell GI; Director EP
J Immunol; 1988 Jul; 141(2):690-8. PubMed ID: 3133414
[TBL] [Abstract][Full Text] [Related]
17. The effect of leucyl-leucine methyl ester on proliferation and Ig secretion of EBV-transformed human B lymphocytes.
Ohlin M; Danielsson L; Carlsson R; Borrebaeck CA
Immunology; 1989 Apr; 66(4):485-90. PubMed ID: 2541070
[TBL] [Abstract][Full Text] [Related]
18. Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells.
Mizutani Y; Bonavida B; Nio Y; Yoshida O
Cancer; 1993 Feb; 71(4):1313-21. PubMed ID: 7679609
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
20. Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicity.
Kaufmann Y; Levanon M; Davidsohn J; Ramot B
J Immunol; 1987 Aug; 139(3):977-82. PubMed ID: 3496395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
